This review explores growth and differentiation factor-15's role as a biomarker in neurodegenerative disorders, suggesting its therapeutic potential.
Growth and differentiation factor-15 (GDF-15) is a multifunctional cytokine that is a distant member of both the transforming growth factor-beta (TGF-β) superfamily and glial cell-derived neurotrophic factor (GDNF) family.1-6 GDF-15 is released in physiologic conditions, such as pregnancy or muscle exercise, but its levels increase particularly in the setting of cellular stress associated with mitochondrial dysfunction and tissue injury.7,8 GDF-15 is a central inhibitor of appetite9,10 and regulates energy homeostasis,2-5 inflammation,11 and carcinogenesis12 (Figure). The effects of GDF-15 signaling can be beneficial or detrimental, depending on their timing, magnitude, and duration.5 Circulating levels of GDF-15 increase with aging and can be markedly elevated in several pathologic conditions, including obesity, diabetes, renal disease, cardiovascular disease, and cancer, where they are typically associated with poor outcomes.13-17 The role of GDF-15 in the pathogenesis and as a biomarker and therapeutic target in these disorders has been extensively reviewed4-6 and will not be further discussed here. Circulating GDF-15 levels also increase in patients with diabetic peripheral neuropathy,18 mitochondrial myopathy,19 neurodegenerative disorders,20-22 and glioma.23 Although experimental evidence suggests that GDF-15 may have a potential neuroprotective role against neurodegeneration22,24 and a detrimental role in glioma,24 its role as a biomarker and therapeutic target in neurologic disorders is yet to be established.
No takes yet. Share an insight, caveat, or question.
Eduardo E. Benarroch (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: